The global biologics safety testing market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, registering a compound annual growth rate (CAGR) of 11.6% during the forecast period.
The market is expanding rapidly as pharmaceutical and biotechnology companies increase investments in monoclonal antibodies, recombinant proteins, vaccines, biosimilars, cell and gene therapies, and mRNA-based therapeutics. These advanced biologic products require rigorous safety testing to ensure they are free from microbial contamination, endotoxins, mycoplasma, adventitious viruses, and other impurities that could compromise patient safety or regulatory approval.
A major structural trend shaping the industry is the growing reliance on contract development and manufacturing organizations (CDMOs) and specialized outsourced testing laboratories. As biologics pipelines become more complex and global manufacturing networks expand, drug developers are increasingly seeking external partners that can provide validated, scalable, and regulatory-compliant safety testing services.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Why Biologics Safety Testing Is Critical
Unlike traditional small-molecule drugs, biologics are produced using living cells and biological systems, making them inherently more susceptible to contamination during development and manufacturing.
Biologics safety testing is designed to detect and control risks associated with:
- Sterility failures
- Bacterial endotoxins
- Mycoplasma contamination
- Bioburden levels
- Adventitious viral agents
- Residual host-cell impurities
- Environmental microbial contamination
Regulatory agencies such as the US FDA, EMA, MHRA, and PMDA require extensive safety testing throughout the product lifecycle, including process development, validation, lot release, and post-approval manufacturing changes.
As biologics manufacturing scales globally, the importance of rapid, sensitive, and reproducible safety testing methods continues to increase.
Key Growth Drivers
Expanding Biologics and Biosimilars Pipeline
The number of biologics and biosimilar candidates entering clinical development continues to rise across therapeutic areas such as:
- Oncology
- Autoimmune diseases
- Rare genetic disorders
- Infectious diseases
- Metabolic disorders
- Neurological conditions
Each new biologic product requires extensive safety testing during cell bank qualification, upstream and downstream processing, formulation development, and commercial manufacturing, directly driving demand for specialized testing solutions.
Growth of CDMOs and Outsourced Manufacturing
Biopharmaceutical companies are increasingly outsourcing manufacturing activities to CDMOs in order to reduce capital expenditure, access specialized expertise, and accelerate time to market.
This shift creates substantial demand for third-party biologics safety testing services, including:
- Sterility testing
- Endotoxin testing
- Mycoplasma detection
- Viral safety testing
- Environmental monitoring
- Batch release testing
CDMOs often require integrated testing partners capable of supporting multiple biologics programs simultaneously while maintaining compliance with global regulatory standards.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
Structural Shift Toward Outsourced Testing
Many pharmaceutical companies are moving away from maintaining large internal microbiology and quality control laboratories. Outsourcing offers several advantages:
- Access to specialized technical expertise
- Faster turnaround times
- Reduced infrastructure investment
- Easier scalability for fluctuating project volumes
- Support for global regulatory submissions
- Availability of advanced rapid microbiological technologies
This structural outsourcing trend is expected to remain a major contributor to market growth through 2031.
Rise of Cell & Gene Therapies and mRNA Products
Advanced therapeutic modalities present unique safety testing challenges. Cell therapies, gene therapies, viral vectors, and mRNA-based products often involve complex biological materials that require highly sensitive contamination detection methods.
These products frequently require:
- Rapid sterility testing for short shelf-life therapies
- Enhanced mycoplasma detection
- Viral vector characterization
- Adventitious agent testing
- Environmental monitoring in highly controlled manufacturing environments
The continued commercialisation of these advanced modalities is creating significant opportunities for innovative safety testing technologies.
Technology Trends Reshaping the Market
Rapid Microbiological Methods (RMMs)
Traditional sterility testing can take several days or even weeks. Rapid microbiological methods are gaining adoption because they offer:
- Faster detection of contamination
- Shorter product release timelines
- Improved manufacturing efficiency
- Reduced inventory holding costs
- Earlier identification of process deviations
These methods are particularly valuable for cell therapies and other time-sensitive biologic products.
Molecular-Based Detection
PCR and other nucleic acid amplification technologies are increasingly used for:
- Mycoplasma detection
- Viral contamination screening
- Microbial identification
- Environmental monitoring applications
Molecular methods provide higher sensitivity and faster results compared with many conventional culture-based techniques.
Automation and Digital Quality Control
Biopharmaceutical manufacturers are investing in automated testing platforms that improve:
- Sample traceability
- Data integrity
- Regulatory compliance
- Laboratory productivity
- Integration with manufacturing execution systems (MES)
Automation is becoming especially important for large-scale commercial biologics manufacturing operations.
Competitive Landscape
The global biologics safety testing market is relatively consolidated, with several large life sciences and laboratory service companies holding significant market share.
Leading companies include:
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Charles River Laboratories (US)
- Laboratory Corporation of America Holdings (US)
- Merck KGaA (Germany)
These companies have strengthened their market positions through:
- New product and service launches
- Strategic acquisitions
- Partnerships and collaborations
- Expansion of global laboratory networks
- Investments in advanced biologics testing technologies
- Development of integrated quality control solutions
Thermo Fisher Scientific: Comprehensive Testing Infrastructure
Thermo Fisher Scientific is one of the most influential participants in the biologics safety testing market. The company offers a broad portfolio covering:
- Sterility testing
- Endotoxin assays
- Mycoplasma detection
- Bioburden testing
- Viral safety testing
- Microbial monitoring reagents
- Analytical instruments and automation platforms
Thermo Fisher supports customers across the entire biologics lifecycle, including:
- Early-stage development
- Process validation
- Clinical manufacturing
- Commercial production
- Ongoing quality control operations
Its extensive global infrastructure and integrated workflow approach make it a preferred partner for both large pharmaceutical companies and emerging biotechnology firms developing advanced biologic therapies.
Roche: Leveraging Diagnostics and Molecular Testing Expertise
F. Hoffmann-La Roche Ltd. maintains a strong position in the biologics safety testing market through its diagnostics and life sciences divisions.
The company provides:
- Molecular diagnostic instruments
- Pathogen detection assays
- Microbial testing reagents
- Automated testing platforms
- Integrated diagnostic workflows
Roche’s expertise in infectious disease diagnostics, molecular biology, and automation is particularly relevant for biologics manufacturers that require highly sensitive pathogen detection and quality control capabilities.
Its focus on integrated, automated, and data-driven testing solutions aligns well with the increasing complexity of advanced biologics manufacturing environments.
Charles River Laboratories: Leader in Outsourced Biologics Testing
Charles River Laboratories has established itself as a leading provider of outsourced biologics safety testing services.
Its service portfolio includes:
- Endotoxin testing
- Sterility testing
- Mycoplasma testing
- Bioburden testing
- Viral safety testing
- Environmental monitoring
- Rapid microbiological testing services
The company’s extensive global laboratory network allows it to support pharmaceutical and biotechnology clients across multiple geographic regions while maintaining consistent regulatory standards.
Charles River has also invested heavily in rapid microbiological methods and integrated testing workflows, helping customers improve turnaround times and accelerate manufacturing release decisions.
Laboratory Corporation of America Holdings: Scalable Global Laboratory Services
Laboratory Corporation of America Holdings (Labcorp) is another important participant in the biologics safety testing market.
The company offers:
- Sterility testing
- Endotoxin testing
- Mycoplasma detection
- Microbial testing services
- Analytical quality control support
- Integrated laboratory services for biologics development
Labcorp’s global laboratory network and scalable service model enable pharmaceutical and biotechnology companies to access centralized testing expertise while supporting distributed development and manufacturing operations.
Its emphasis on integrated laboratory services and flexible outsourcing models makes it well positioned to benefit from the growing trend toward externalized biologics testing.
Merck KGaA: Supporting Bioprocessing and Quality Control
Through its Life Science business, Merck KGaA provides products and technologies that support biologics safety testing workflows, including:
- Sterility testing media
- Endotoxin detection solutions
- Microbial monitoring products
- Filtration technologies
- Sample preparation reagents
- Bioprocess quality control tools
Merck’s strong presence in bioprocessing, filtration, and life science research allows it to support both upstream manufacturing operations and downstream quality control activities within biologics production facilities.
Emerging Opportunities
Cell and Gene Therapy Manufacturing
Commercialization of CAR-T therapies, stem cell therapies, gene-edited products, and viral vector-based therapeutics is creating substantial demand for specialized safety testing solutions capable of supporting:
- Short manufacturing timelines
- Small batch sizes
- High-value personalized therapies
- Stringent contamination control requirements
mRNA Therapeutics and Vaccines
The success of mRNA vaccine platforms has accelerated broader investment in mRNA therapeutics for infectious diseases, oncology, and rare diseases. These products require sophisticated testing strategies for:
- Raw material quality
- Sterility assurance
- Residual DNA detection
- Lipid nanoparticle characterization
- Environmental contamination control
Continuous Manufacturing
As biologics manufacturers adopt more continuous and automated production processes, there is growing demand for real-time and at-line safety testing technologies that can provide faster feedback and support continuous process verification.
hallenges Facing the Market
Despite its strong growth outlook, the biologics safety testing market faces several challenges.
High Cost of Advanced Testing Technologies
Implementing molecular testing platforms, automated microbiology systems, and rapid sterility testing technologies can require significant capital investment, particularly for smaller biotechnology companies and regional manufacturers.
Complex Regulatory Requirements
Global biologics manufacturers must comply with multiple regulatory frameworks, including differing requirements for sterility validation, viral safety studies, and mycoplasma testing, increasing operational complexity.
Skilled Workforce Shortages
Advanced biologics safety testing requires expertise in microbiology, molecular biology, virology, analytical validation, and GMP quality systems. Recruiting and retaining qualified personnel remains a challenge for many organizations.
Increasing Testing Complexity
Emerging modalities such as gene therapies, oncolytic viruses, engineered cell products, and combination biologics often require customized testing strategies that are more complex than traditional biologics quality control programs.
Future Outlook Through 2031
The biologics safety testing market is expected to maintain strong double-digit growth through 2031 as the biopharmaceutical industry continues shifting toward advanced biologics, personalized medicines, and outsourced manufacturing models.
Several long-term trends are expected to sustain market expansion:
- Continued growth of monoclonal antibodies and biosimilars
- Expansion of global CDMO capacity
- Increasing adoption of rapid microbiological methods
- Greater automation of quality control laboratories
- Rising commercialisation of cell and gene therapies
- Broader use of molecular-based contamination detection technologies
The projected increase from USD 5.57 billion in 2026 to USD 9.66 billion by 2031 reflects the critical role that safety testing plays in ensuring the quality, safety, and regulatory compliance of increasingly complex biologic products.
Conclusion
Biologics safety testing has become an essential pillar of modern biopharmaceutical development and manufacturing. As the industry expands beyond traditional biologics into cell therapies, gene therapies, viral vectors, and mRNA-based therapeutics, the need for rapid, sensitive, scalable, and regulatory-compliant safety testing solutions is becoming more important than ever.
Leading companies such as Thermo Fisher Scientific, Roche, Charles River Laboratories, Labcorp, and Merck KGaA are strengthening their positions through technology innovation, global laboratory expansion, integrated service offerings, and strategic investments in advanced biologics testing capabilities.
With strong demand driven by outsourced testing, CDMO expansion, advanced therapeutic modalities, and increasingly stringent regulatory expectations, the biologics safety testing market is well positioned for substantial growth through 2031 and beyond, making it one of the most strategically important segments within the broader biopharmaceutical quality and safety ecosystem.
Inquire Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34624144